Skip to main content
Smart Investors Daily
RL

AMEX · RLY

SPDR SSgA Multi-Asset Real Return ETF

Financial Services · Asset Management

$35.14

Down-$0.65 (-1.82%)

Updated Nov 19, 2026, 11:56 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
645.9M
P/E ratio
—
Dividend yield
2.25%
52-week range
$34.23 – $38.38
Volume
184.94K
Avg. volume
68.6K

Price performance · RLY

RLY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

RLY closed at $35.14 after 21 trading sessions, down 5.88% for the selected period.

Last close
$35.14
Period change
-5.88%
Period low
$35.14
Period high
$37.38
Daily close
View OHLC price history
RLY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$35.50$35.50$35.08$35.135184.94K
Nov 17, 2026$35.94$36.0632$35.6625$35.78119.48K
Nov 16, 2026$36.35$36.35$35.885$35.8997.7K
Nov 13, 2026$36.58$36.58$36.40$36.47417.62K
Nov 12, 2026$36.57$36.57$36.33$36.48185.99K
Nov 11, 2026$36.30$36.5299$36.30$36.50177.26K
Nov 10, 2026$36.21$36.39$36.065$36.35134.15K
Nov 9, 2026$36.33$36.65$36.33$36.62234.45K
Nov 6, 2026$35.96$36.38$35.96$36.27227.29K
Nov 5, 2026$36.82$36.94$36.275$36.31198K
Nov 4, 2026$37.00$37.00$36.55$36.63183.54K
Nov 3, 2026$36.80$36.90$36.69$36.75176.32K
Nov 2, 2026$37.32$37.32$36.94$36.94302.96K
Oct 30, 2026$37.21$37.41$37.21$37.38171.62K
Oct 29, 2026$37.14$37.38$37.14$37.38172.75K
Oct 28, 2026$37.38$37.38$37.13$37.30141.6K
Oct 27, 2026$37.16$37.32$37.16$37.27234.68K
Oct 26, 2026$37.11$37.38$37.10$37.29248.04K
Oct 23, 2026$37.07$37.4199$37.07$37.38171.98K
Oct 22, 2026$37.38$37.38$36.885$37.13129.52K
Oct 21, 2026$37.21$37.34$37.21$37.33138.03K

Latest RLY news

The latest Smart Investors Daily articles mentioning RLY.

RLY research

Overview

Company profile and research snapshot.

Company profile

Under normal circumstances, the Adviser invests at least 80% of the net assets of the fund among ETPs that provide exposure to the following primary asset classes: (i) inflation protected securities issued by the United States government; (ii) domestic and international real estate securities; (iii) commodities; (iv) publicly-traded domestic and international infrastructure companies; and (iv) publicly-traded companies in natural resources and/or commodities businesses.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Dec 12, 2025

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.